ASK PHARM(002755)2023-05-11 02:20Group 1: Company Overview and R&D Focus - The company, Beijing Ausun Pharmaceutical Co., Ltd., focuses on four major therapeutic areas: digestion, oncology, anti-infection, and chronic diseases [1] - The R&D investment is expected to maintain the same scale as in 2022 for the next 2-3 years, with a careful evaluation of clinical and commercial value for each project [2] - As of December 2022, the R&D team consists of 372 members, with a strong background in innovative drug development [2] Group 2: R&D Strategy and Pipeline - The company has established a clinical team of over 100 members with extensive experience in innovative drug development [3] - The R&D strategy includes internal incubation, licensing in, and business development to enhance the pipeline [3] - The small molecule pipeline includes innovative anti-tumor drugs like ASK120067, which is a third-generation EGFR TKI for NSCLC, and ASK202, a c-Met inhibitor for resistant patients [4] Group 3: Clinical Progress and Product Launches - The innovative drug ASKB589 is currently in Phase II clinical trials, with positive safety and tolerability results reported [4] - The company has a self-operated and third-party combined approach for product promotion, with over 200 members in the self-operated team [3] - Two IL-15 cytokine drugs, ASKG315 and ASKG915, are in clinical trials, with ASKG915 approved by the FDA for clinical trials in the U.S. [5]